Go for Glenmark Pharma than Ranbaxy or Wockhardt: Jagannadham Thunuguntla

In a chat with ET Now, Jagannadham Thunuguntla, Equity Head, SMC Capitals shares his views on the pharma space.

ET Now: What do you do with pharma names like Ranbaxy and Wockhardt?

Jagannadham Thunuguntla: One has to bet on these two names. Wockhardt makes a little more sense than Ranbaxy, but if somebody is very keen on pharma, we have a better perspective on Glenmark Pharma than Ranbaxy or Wockhardt.

ET Now: No why do you like Glenmark?

Jagannadham Thunuguntla: The management appears to be a lot more aggressive and clear in their approach. If you see the track record in comparison to many other pharma segment, there are no much eyebrow raising or regulatory disturbances in Glenmark. All other names have one or the other hiccups. It make sense to be safe than being sorry.